Newstral
Samsung Bioepis
- Why Did Merck Stock Rise 65%?Forbes
- Alexion and Samsung Bioepis Settle Soliris® Biosimilar Patent Proceedings for Epysqli®jdsupra.com
- Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilarjdsupra.com
- Amgen Files BPCIA Lawsuit Against Samsung Bioepis Prolia® / Xgeva® Proposed Biosimilar SB16jdsupra.com
- EYLEA® Biosimilar Updates: Sandoz’s Enzeevu™ (aflibercept-abzv) FDA Approved, Regeneron Dismisses IPR Appealsjdsupra.com
- Recent PTAB Developments for Regeneron’s Aflibercept-Dosing Patentsjdsupra.com
- Amgen Files BPCIA Complaint Against Samsung Bioepsis Regarding Denosumabjdsupra.com
- FDA Accepts Bio-Thera’s aBLA for Proposed Stelara® (Ustekinumab) Interchangeable BAT2206jdsupra.com
- Regeneron Dismisses IPR Appeals and Disclaims EYLEA® (aflibercept) Patentjdsupra.com
- FDA Approves Second Soliris® (eculizumab) Interchangeable Biosimilar - Samsung Bioepis’s Epysqli® (eculizumab-aagh)jdsupra.com
- With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?Forbes
- Updates on Aflibercept Biosimilar Approvals and BPCIA Litigationjdsupra.com
- The First Biosimilar Disputes at the Unified Patent Court (UPC)jdsupra.com
- FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy)jdsupra.com
- Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Ordersjdsupra.com
- Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDAjdsupra.com
- MDL Panel Grants Transfer of Aflibercept BPCIA Casejdsupra.com
- Updates on Aflibercept BPCIA Litigation - January 2023jdsupra.com
- Ustekinumab Antitrust Litigationjdsupra.com
- Regeneron’s Disputes with Celltrion, Samsung Bioepis, and Formcycon on Service and Personal Jurisdiction in Aflibercept BPCIA Litigationjdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.